Hepion Pharmaceuticals Appoints Accomplished Life Sciences Industry Veteran, Dr. Launa J. Aspeslet, as Chief Operating Officer
June 14, 2022 08:00 ET
|
Hepion Pharmaceuticals, Inc.
- Dr. Aspeslet joins the Company to support rencofilstat’s clinical program - EDISON, N.J., June 14, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage...
Hepion Pharmaceuticals Urges Shareholders to Vote “FOR” All Proposals Ahead of its Upcoming Annual Meeting
May 31, 2022 16:30 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
CORRECTING and REPLACING - Hepion Pharmaceuticals, Inc.
May 27, 2022 08:54 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., May 27, 2022 (GLOBE NEWSWIRE) -- In the press release issued earlier today by Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), we've been informed by the company that in both the headline...
Hepion Pharmaceuticals Highlights Upcoming Phase 2 Clinical Trials of Recofilstat at 5th Global NASH Congress
May 27, 2022 08:00 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., May 27, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
Hepion Pharmaceuticals Announces Clinical Collaboration with HepQuant in Phase 2b NASH Trial
May 03, 2022 08:00 ET
|
Hepion Pharmaceuticals, Inc.
- HepQuant Evaluation Offers Sensitive Measurement of Hepatic Function and Correlation with Clinical Outcomes - - Dedicated Phase 2b Trial Supports Overarching NASH Program for Rencofilstat - -...
Hepion Pharmaceuticals to Present at the Q1 Investor Summit Conference
March 07, 2022 08:00 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
Hepion Pharmaceuticals Appoints World-Renowned Hepatologist, Dr. Eddie C. Cheung, to Lead the Company’s Strategic Medical Affairs in Asia
February 15, 2022 08:00 ET
|
Hepion Pharmaceuticals, Inc.
- Dr. Cheung, who has dedicated his career to NASH, hepatocellular carcinoma, fatty liver disease, and viral hepatitis will endeavor to advance Hepion’s business development and partnering efforts in...
Hepion Pharmaceuticals to Present at BIO CEO & Investor Conference
February 14, 2022 08:00 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
Hepion Pharmaceuticals’ Rencofilstat, in Combination with an Immune Checkpoint Inhibitor, Demonstrates Synergistic Anti-Tumor Activity in a Nonclinical Liver Cancer Study
January 26, 2022 08:00 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
Hepion Pharmaceuticals Announces Death of Director, Thomas Adams
January 12, 2022 08:00 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- It is with profound sadness that Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) announces the passing of Thomas Adams, Ph.D., a member of its Board of...